Year
2025
Organisation
Summary
This research investigates aggressive childhood medulloblastoma using CRISPR-Cas9 to identify genes essential for tumor survival. It identifies DNMT1 as a key driver of tumor growth and shows that the existing drug decitabine can inhibit this pathway, offering a promising, potentially less toxic therapeutic strategy pending future clinical validation.